Check-Cap Ltd. (CHEK)
USD 0.67
(-0.95%)
USD 0.67
(-0.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.64 Million USD | 10.09% |
| 2022 | -18.69 Million USD | -14.69% |
| 2021 | -16.98 Million USD | -24.17% |
| 2020 | -13.68 Million USD | 1.22% |
| 2019 | -13.95 Million USD | -27.83% |
| 2018 | -10.43 Million USD | -10.89% |
| 2017 | -9.84 Million USD | -10.21% |
| 2016 | -8.93 Million USD | 27.8% |
| 2015 | -12.23 Million USD | -209.82% |
| 2014 | -4.45 Million USD | -8.36% |
| 2013 | -3.89 Million USD | -1.54% |
| 2012 | -3835.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -4.06 Million USD | -45.06% |
| 2023 Q2 | -4.6 Million USD | 3.18% |
| 2023 FY | - USD | 10.09% |
| 2023 Q1 | -4.75 Million USD | -16.97% |
| 2023 Q3 | -2.8 Million USD | 39.16% |
| 2022 FY | - USD | -14.69% |
| 2022 Q3 | -4.95 Million USD | -3.02% |
| 2022 Q4 | -4.06 Million USD | 17.88% |
| 2022 Q2 | -4.8 Million USD | 17.28% |
| 2022 Q1 | -5.8 Million USD | -5.39% |
| 2021 Q3 | -4.21 Million USD | -8.67% |
| 2021 Q2 | -3.87 Million USD | -10.33% |
| 2021 FY | - USD | -24.17% |
| 2021 Q4 | -5.51 Million USD | -30.83% |
| 2021 Q1 | -3.51 Million USD | 9.71% |
| 2020 Q4 | -3.89 Million USD | -8.35% |
| 2020 Q1 | -3.38 Million USD | 11.29% |
| 2020 Q2 | -2.91 Million USD | 13.88% |
| 2020 Q3 | -3.59 Million USD | -23.22% |
| 2020 FY | - USD | 1.22% |
| 2019 Q2 | -3.46 Million USD | -10.55% |
| 2019 FY | - USD | -27.83% |
| 2019 Q3 | -3.53 Million USD | -1.96% |
| 2019 Q1 | -3.13 Million USD | 8.84% |
| 2019 Q4 | -3.81 Million USD | -7.95% |
| 2018 Q3 | -2.76 Million USD | -4.46% |
| 2018 FY | - USD | -10.89% |
| 2018 Q4 | -3.44 Million USD | -24.37% |
| 2018 Q2 | -2.64 Million USD | -28.42% |
| 2018 Q1 | -2.06 Million USD | -2.28% |
| 2017 Q2 | -2.77 Million USD | -1.58% |
| 2017 Q3 | -7.9 Million USD | -185.23% |
| 2017 Q4 | -2.01 Million USD | 74.48% |
| 2017 FY | - USD | -10.21% |
| 2017 Q1 | -2.72 Million USD | -13.63% |
| 2016 Q3 | -1.72 Million USD | 11.43% |
| 2016 FY | - USD | 27.8% |
| 2016 Q1 | -2.86 Million USD | 5.09% |
| 2016 Q2 | -1.94 Million USD | 32.28% |
| 2016 Q4 | -2.4 Million USD | -39.45% |
| 2015 Q2 | -2.54 Million USD | 33.72% |
| 2015 Q1 | -3.84 Million USD | -290.06% |
| 2015 Q4 | -3.02 Million USD | -1.17% |
| 2015 Q3 | -2.98 Million USD | -17.22% |
| 2015 FY | - USD | -209.82% |
| 2014 Q3 | -881 Thousand USD | 20.77% |
| 2014 Q1 | -1.09 Million USD | -6.54% |
| 2014 Q2 | -1.11 Million USD | -1.83% |
| 2014 Q4 | -986 Thousand USD | -11.92% |
| 2014 FY | - USD | -8.36% |
| 2013 Q2 | -953 Thousand USD | -3.31% |
| 2013 Q4 | -1.02 Million USD | 0.0% |
| 2013 FY | - USD | -1.54% |
| 2013 Q1 | -922.5 Thousand USD | 0.0% |
| 2013 Q3 | -1.02 Million USD | -7.56% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 84.988% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -84.015% |
| Aspira Women's Health Inc. | -16.49 Million USD | -7.022% |
| Biodesix, Inc. | -37.1 Million USD | 52.432% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -610.175% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -131.332% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -131.332% |
| Bionano Genomics, Inc. | -213.6 Million USD | 91.738% |
| CareDx, Inc | -89.65 Million USD | 80.315% |
| Castle Biosciences, Inc. | -45.02 Million USD | 60.801% |
| DarioHealth Corp. | -53.49 Million USD | 67.008% |
| Exact Sciences Corporation | 41.87 Million USD | 142.146% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 62.088% |
| Guardant Health, Inc. | -433.3 Million USD | 95.927% |
| ICON Public Limited Company | 1.63 Billion USD | 101.082% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 101.449% |
| Illumina, Inc. | -608 Million USD | 97.097% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -100.313% |
| iSpecimen Inc. | -9.1 Million USD | -93.866% |
| Standard BioTools Inc. | -54.45 Million USD | 67.591% |
| MDxHealth SA | -30.46 Million USD | 42.074% |
| 23andMe Holding Co. | -291.87 Million USD | 93.953% |
| Medpace Holdings, Inc. | 363.15 Million USD | 104.86% |
| Myriad Genetics, Inc. | -67.8 Million USD | 73.969% |
| Mainz Biomed B.V. | -25.01 Million USD | 29.436% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -80.372% |
| NeoGenomics, Inc. | -17.6 Million USD | -0.239% |
| Neogen Corporation | 182.59 Million USD | 109.666% |
| Inotiv, Inc. | -26.5 Million USD | 33.415% |
| Natera, Inc. | -383.27 Million USD | 95.395% |
| OpGen, Inc. | -29.51 Million USD | 40.195% |
| OPKO Health, Inc. | -65.51 Million USD | 73.062% |
| Psychemedics Corporation | -251 Thousand USD | -6931.474% |
| Prenetics Global Limited | -47.89 Million USD | 63.151% |
| Prenetics Global Limited | -47.89 Million USD | 63.151% |
| Precipio, Inc. | -4.31 Million USD | -308.731% |
| Personalis, Inc. | -96.8 Million USD | 81.769% |
| RadNet, Inc. | 292.78 Million USD | 106.028% |
| Sera Prognostics, Inc. | -35.28 Million USD | 49.984% |
| Sotera Health Company | 514.14 Million USD | 103.433% |
| Neuronetics, Inc. | -22.75 Million USD | 22.453% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -946.177% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -946.177% |
| Trinity Biotech plc | -24.09 Million USD | 26.762% |
| T2 Biosystems, Inc. | -43.87 Million USD | 59.774% |
| Twist Bioscience Corporation | -176.7 Million USD | 90.012% |
| Exagen Inc. | -19.15 Million USD | 7.853% |